To the Editor:

We read with interest the manuscript by Ji and coworkers, reporting that among 202 Chinese individuals with COVID-19,[@bib1] those with likely metabolic-associated fatty liver disease (MAFLD) had a higher probability of abnormal liver function tests and disease progression than those without. Obesity and dysmetabolism are highly associated with severe COVID-19,[@bib2] raising the possibility that fatty liver directly mediates inflammation and hypercoagulation leading to respiratory and systemic complications of COVID-19.[@bib3] Alternatively, fatty liver may indirectly favor replication of the SARS-CoV-2 virus.[@bib4] However, several confounders, *e.g.* an independent role of insulin resistance, and reverse causation, *e.g.* the impact of SARS-CoV-2 and treatments on fatty liver, may complicate the interpretation of these initial retrospective observations.

Mendelian randomization is an epidemiological framework that bypasses confounding and reverse causation by using genetic variation as an instrument to establish the causal role of modifiable risk factors in disease pathogenesis.[@bib5] We previously developed a genetic risk score (GRS) for MAFLD based on the weighted effect of risk variants in *PNPLA3-TM6SF2-MBOAT7-GCKR* on hepatic fat in the general population.[@bib6] Exploiting this robust instrument, we showed that hepatic fat has a causal role in determining liver fibrosis and insulin resistance.[@bib6]

Herein, we examined the impact of the MAFLD-GRS on the risk of COVID-19 in individual data of participants of the UK Biobank (UKBB) cohort. The UKBB comprises 502,640 individuals aged between 40 and 69 years.[@bib7] Baseline assessment, medical history and biological samples are available, including also genetic data. We had access to these data with application \#37142. UKBB started to release COVID-19 test results from March 16th 2020 (data-field 40100), and given that the tests were mainly restricted to hospitalized patients with symptoms, positive test results can be considered as a proxy of severe disease. As of May 2^nd^ 2020, test results were available for 4,119 individuals (2,770 confirmed inpatients; data were only partially available for the rest). We restricted the analysis to the subset of white British ancestry. After applying quality control ([supplementary data](#appsec1){ref-type="sec"}), the remaining number of individuals was 1,460, of whom 526 were positive (case) and 934 were negative (control) for SARS-CoV-2, respectively. Of these, 835 (57%) were confirmed inpatients. Results are shown in [Table 1](#tbl1){ref-type="table"} , left panel. The GRS was not associated with an increased risk of COVID-19, as also observed for carriage of each variant included in the score (all *p* values \>0.1). These results suggest that genetic predisposition to hepatic fat accumulation does not increase *per se* the predisposition towards severe COVID-19, and that MAFLD does not play a causal role of in this condition.Table 1Impact of genetic predisposition to MAFLD on the risk of developing COVID-19 in the UKBB (526 cases and 934 controls), and on the hepatic mRNA expression of cellular SARS-CoV-2 receptors in 125 obese individuals.Genetic instrumentUKBB association studyGene expression*p* value[∗](#tbl1fnlowast){ref-type="table-fn"}OR95% CIEstimate*p* value[°](#tbl1fndegree){ref-type="table-fn"}**GRS** Unadjusted0.46*ACE2*+37 ± 240.13 Model 10.700.900.51--1.56*CTSL*−130 ± 2010.54 Model 20.690.890.51--1.56*TMPRSS2*+19 ± 890.83 Model 30.680.890.51--1.56*PYKFYVE*−49 ± 860.57***PNPLA3*** p.I148M Unadjusted0.06*ACE2*+13 ± 70.06 Model 10.120.860.71--1.04*CTSL*54 ± 610.80 Model 20.130.860.71--1.04*TMPRSS2*+13 ± 260.61 Model 30.130.860.71--1.04*PYKFYVE*2 ± 250.95***TM6SF2*** p.E167K Unadjusted0.46*ACE2*+5 ± 170.77 Model 10.481.100.85--1.42*CTSL*−17 ± 620.79 Model 20.521.090.84--1.41*TMPRSS2*−76 ± 1460.60 Model 30.531.090.84--1.41*PYKFYVE*+29 ± 600.62***MBOAT7*** rs738409 C\>G Unadjusted0.61*ACE2*−7 ± 60.23 Model 10.451.060.91--1.23*CTSL*+5 ± 500.91 Model 20.501.050.90--1.23*TMPRSS2*−10 ± 210.62 Model 30.501.050.90--1.23*PYKFYVE*−20 ± 210.34***GCKR*** p.P446L Unadjusted0.34*ACE2*−1 ± 60.89 Model 10.321.080.93--1.26*CTSL*−11 ± 540.83 Model 20.281.090.93--1.28*TMPRSS2*−3 ± 230.90 Model 30.281.090.93--1.28*PYKFYVE*−18 ± 220.42[^1][^2][^3][^4]

These results should be interpreted with caution for several reasons: they were obtained in an initial set of cases without detailed characterization, and for a possible lack of power to detect the association. However, the current sample size clearly had the power to detect a \>6-fold higher risk of severe COVID-19 conferred by MAFLD, as reported by Ji *et al*.[@bib1] We actually detected a trend of protection against COVID-19 conferred by rs738409, encoding for the p.I148M *PNPLA3* variant, which is a major genetic determinant of hepatic inflammation.[@bib5] ^,^ [@bib8] Future larger studies are warranted to formally test this hypothesis. A possible reason for differential susceptibility to severe COVID-19 is related to altered expression of SARS-CoV-2 cellular receptors.[@bib9] We therefore looked at the impact of genetic risk variants on the hepatic mRNA expression of *ACE2*, *CTSL*, *TMPRSS2* and *PYKFYVE* [@bib9] in a cohort of 125 obese individuals.[@bib8] We found no significant impact of MAFLD-GRS and single variants on the expression of known viral receptors. However, we observed a trend towards higher *ACE2* expression associated with carriage of the p.I148M *PNPLA3* variant that was not statistically significant (*p* = 0.06).

In conclusion, the first available genetic data are not consistent with a strong predisposition conferred by MAFLD to the development of severe COVID-19. Larger prospective studies including the role of obesity, dyslipidemia and type 2 diabetes are warranted to understand the impact of genetic predisposition to MAFLD on COVID-19 susceptibility and severity, namely on the risk of hospitalization and mortality.
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[^1]: Model 1: adjusted for age, sex, BMI, PC1-10 (ethnicity), assessment center, array batch; Model 2: further adjusted for inpatient (origin of test sample, as coded in data-coding 1855); Model 3: further adjusted for diagnosis of diabetes.

[^2]: BMI, body mass index; GRS, genetic risk score; MAFLD, metabolic-associated fatty liver disease; OR, odds ratio; UKBB, UK Biobank.

[^3]: At binary logistic regression analysis. GRS of MAFLD, based on the weighted impact of genetic risk variants on hepatic fat content.

[^4]: At generalized linear model adjusted for age, sex, BMI, and type 2 diabetes.
